Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Research & Studies
Share your love
UnitedHealthcare updates Glaucoma Surgical Treatments policy
(Image Credit: AdobeStock/gguy) UnitedHealthcare (UHC) has updated its Glaucoma Surgical Treatments policy to include goniotomy, trabeculotomy, canaloplasty (ab interno), combined canaloplasty (ab interno), and trabeculotomy procedures when deemed medically necessary for treating mild to moderate open-angle glaucoma (OAG) and cataracts…
Beacon Therapeutics reports positive phase 2 results for gene therapy in X-linked retinitis pigmentosa
(Image Credit: AdobeStock/Dmitrii Kotin) Beacon Therapeutics recently revealed topline data results for 2 of the company’s phase 2 trials—SKYLINE and DAWN, both investigating laruparetigene zovaparvovec (laru-zova) in patients with X-linked retinitis pigmentosa (XLRP).1 The data was presented during the 2025…
Positive topline data announced from AVONELLE-X and SALWEEN trials
(Image credit: ©pressmaster/AdobeStock) Roche recently announced new data from the AVONELLE-X and SALWEEN trials of Vabysmo (faricimab).1 These trial data were presented at the 25th European Society of Retina Specialists (EURETINA) Annual Congress held September 4-7 in Paris. Positive safety,…
Amir Kashani on biomarkers for Alzheimer disease
(Image credit: AdobeStock/Pixel Matrix) Amir H. Kashani, MD, PhD, is a professor of ophthalmology at the Wilmer Eye Institute in Johns Hopkins University in Baltimore, Maryland. In an interview with Ophthalmology Times, Kashani discussed a research paper on OCT-A angiography’s…
Opus Genetics doses first patient in LYNX-3, phase 3 trial of phentolamine ophthalmic solution 0.75%
(Image Credit: AdobeStock/svetlanais) Opus Genetics has dosed the first patient in LYNX-3, its pivotal phase 3 clinical trial of phentolamine ophthalmic solution 0.75% in treating significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision. Night-vision disturbances, which…
Celltrion announces phase 3 trial data for EYDENZELT
(Image credit: ©HockleyM2) Celltrion recently announced 52-week findings from its global phase 3 clinical trial for its ophthalmic treatment candidate, EYDENZELT.1 EYDENZELT, a biosimilar of EYLEA (aflibercept), is Celltrion’s ophthalmic treatment candidate for the treatment of multiple retinal diseases, including…
Hispanic patients with POAG had lower success rates after glaucoma surgery compared with patients of European descent
(Image credit: AdobeStock/Vladislav) A study reported lower success rates associated with initial trabeculectomy with mitomycin C (MMC) in Hispanic patients compared with those who were of European descent. This information may be useful when considering patient candidacy for glaucoma surgery,1…
Glaucoma-focused session with Angelo P. Tanna, MD, launches Northwestern University’s “Dinner with the Experts” series
Kicking off Northwestern University’s “Dinner with the Experts” series, Angelo P. Tanna, MD, leads a deep dive into OCT and perimetry for glaucoma progression on September 9, 2025. (Image credit: AdobeStock/FourLeafLover) As part of its new “Dinner with the Experts…
Alcon completes acquisition of LumiThera
(Image Credit: AdobeStock/Timon) Alcon has completed its planned acquisition of LumiThera, Inc, which was announced earlier in July of this year.1,2 According to Alcon, the acquisition includes the noninvasive Valeda photobiomodulation (PBM) device for the treatment of early and intermediate dry…
Inside Northwestern University’s “Dinner with the Experts” educational series with Robert S. Feder, MD
The Northwestern University Department of Ophthalmology is launching “Dinner with the Experts – Cases, Updates, and Clinical Pearls,” a collaborative space for sharing ophthalmic knowledge and practical takeaways. (Image credit: AdobeStock/Harsha) The Northwestern University Department of Ophthalmology is launching a…